Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of FOR46 in mCRPC
NCT03575819Phase 1Completed
- Sponsor
- Fortis Therapeutics
- Start
- Feb 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Fortis Therapeutics. Primary endpoints: Occurrence of toxicity, Occurrence of dose-limiting toxicities and 1 more. Started Feb 2019; status: completed.
02
Drugs
FG-3246
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03575819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575819.